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We report that B cell–activating factor of the tumor necrosis factor (TNF) family (BAFF) is 
expressed in the normal human brain at 
 
 
 
10% of that in lymphatic tissues (tonsils and 
adenoids) and is produced by astrocytes. BAFF was regularly detected by enzyme-linked 
immunosorbent assay in brain tissue lysates and in normal spinal fluid, and in astrocytes by 
double fluorescence microscopy. Cultured human astrocytes secreted functionally active BAFF 
after stimulation with interferon-
 
 
 
 and TNF-
 
 
 
 via a furin-like protease-dependent pathway. 
BAFF secretion per cell was manifold higher in activated astrocytes than in monocytes and 
macrophages. We studied brain lesions with B cell components, and found that in multiple 
sclerosis plaques, BAFF expression was strongly up-regulated to levels observed in lymphatic 
tissues. BAFF was localized in astrocytes close to BAFF-R–expressing immune cells. BAFF 
receptors were strongly expressed in situ in primary central nervous system (CNS) lymphomas. 
This paper identifies astrocytes as a nonimmune source of BAFF. CNS-produced BAFF may 
support B cell survival in inflammatory diseases and primary B cell lymphoma.
 
BAFF (B cell–activating factor of the TNF
family; also named BLyS) plays a crucial role in
B cell development, survival, and production
of Ig (1). Studies on BAFF transgenic mice and
patients with rheumatoid diseases indicate that
overexpression of BAFF is linked to the devel-
opment of autoimmune pathology (1).
Until now, myeloid cells, namely mono-
cytes, macrophages, dendritic cells (2), and
neutrophils (3), as well as unidentified non-
bone marrow–derived radioresistant cells (4),
have been considered as sources of BAFF.
In different immunopathologies, the brain
provides a fostering environment to B cells:
primary central nervous system (CNS) lym-
phomas are usually of B cell origin (5). The
cerebrospinal fluid (CSF) of patients with
chronic infectious and autoimmune diseases of
the CNS typically contains remarkably stable
oligoclonal Ig bands (6). In the CNS of multi-
ple sclerosis (MS) patients clonally expanded B
cells and plasma cells persist (7–9), ectopic B
cell follicles develop in the meninges of pa-
tients with secondary progressive MS (10), and
B cell differentiation may be recapitulated in
the CNS of MS patients (11).
Our paper establishes astrocytes as BAFF
producers and suggests that CNS-derived BAFF
might foster B cell survival in MS and primary
CNS lymphoma.
 
RESULTS AND DISCUSSION
BAFF in the normal CNS
 
BAFF transcription was analyzed in 17 differ-
ent normal brain samples from four adults in-
cluding gray and white matter of the cerebrum
and the cerebellum. Similar levels of transcripts
were detected in each specimen (Figs. 1 and
2). The level of BAFF mRNA in the normal
brain was almost 10% of that detected in ton-
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sils or adenoids (Fig. 2). Similar results were obtained with
PPIA (Fig. 2) or with GAPDH (not depicted) as housekeep-
ing gene.
The transcript level of BAFF was quantified in a series of
other tissues. BAFF expression was detectable in heart, skele-
tal muscle, pancreas, kidney, skin with adipose tissue, and
liver at similar levels as in the CNS (i.e., in the range of
0.03–0.1% PPIA). In the lung, the BAFF levels were slightly
higher, reaching 0.18% PPIA. Although the present paper
identifies astrocytes as BAFF producers in the CNS (Figs. 3
and 4), further studies might establish whether in other tis-
sues resident macrophages (particularly in lung) or parenchy-
mal cells are responsible for local BAFF transcription.
An alternative splice variant lacking exon 3 (
 
 
 
BAFF) has
been identified in mouse and human myeloid cells (12). We
detected 
 
 
 
BAFF, which was less abundant than the full-
length isoform, in all brain specimens as well as in lymphatic
tissue (Fig. 1).
BAFF-expressing cells had the morphology of astrocytes.
They were found in three normal brains in the parenchyma
and in the perivascular area both in the gray and in the white
matter (Fig. 3, A–D). BAFF
 
 
 
 cells displayed long processes
that extended to the perivascular area (Fig. 3 A).
In tonsils and adenoids, BAFF was detected on a few
scattered cells without a clear distribution pattern. The fre-
quency of BAFF-labeled cells differed considerably in differ-
ent tonsil specimens. The labeled cells appeared in germinal
centers (Fig. 3 O), T cell areas, and in some specimens also
in the connective tissue (not depicted).
BAFF was detected in brain tissue by ELISA at a concen-
tration of 
 
 
 
140 pg/mg protein lysate, whereas 
 
 
 
5 ng/mg
Figure 1. BAFF transcripts in brain specimens and lymphatic tissue. 
RT-PCR detected full-length BAFF and the splice variant  BAFF in human 
CNS and lymphatic tissue. Genomic DNA (gDNA) and H2O served as controls.
Figure 2. BAFF expression in normal CNS, MS lesions, and primary 
CNS lymphomas. Expression level of individual tissue samples was deter-
mined by quantitative PCR, and the median of each group is indicated. 
Mann-Whitney rank sum test was used for statistical analysis. Note that 
the BAFF levels in normal CNS and primary CNS lymphoma were not zero, 
but clearly detectable in each specimen with a mean of 0.034% PPIA.
Figure 3. BAFF and BAFF-R–expressing cells in the normal CNS, MS, 
and primary CNS lymphoma. (A–D) BAFF in the normal CNS. (A) Molecular 
stratum and (B) granular stratum were from the cerebellum, (C and D) from 
the cerebrum. BAFF immunolocalized to scattered astrocytes in the perivas-
cular area (A) and in the parenchyma (B–D). Similar staining patterns were 
observed with the two different BAFF-specific mAbs B1A3.2 (A–C) and 
A9C9.1 (D). (E–N) BAFF-specific astrocytes in different MS lesions. (E–G and 
M) Patient 1 (acute lesion); (H–L) patient 2 (chronic lesions); and (N) patient 
3 (chronic lesion). BAFF-positive astrocytes are detected in the perivascular 
area (H–L) and in the parenchyma (H–J, M, and N). Double stainings are 
shown for GFAP (F and I, red), BAFF (E and H, green), and the overlays 
(G and J). Confocal microscopy (H–J) shows that BAFF-positive astrocytes 
form a network in the parenchyma and in the perivascular area. The two 
different BAFF-specific mAbs give similar staining patterns (K and L). 
(M) BAFF on astrocytes is demonstrated in the vicinity of infiltrating 
immune cells. The mAb B1A3.2 (E, G, H, J, K, M, N) and the mAb A9C9.1 (L) 
were applied. (O) A scattered cell in the germinal center of a tonsil is 
stained for BAFF (mAb B1A3.2). (P) BAFF-R expression on infiltrating im-
mune cells within an acute MS lesion (patient 1). (Q) BAFF-R on the densely 
packed tumor cells on a primary CNS lymphoma. Sections were developed 
with diaminobenzidine that resulted in a brown color; nuclei were stained 
blue with hematoxylin (A–D and K–Q). Bars, 20  m. 
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was observed in tonsils/adenoids. The amount of BAFF de-
tected in normal brain tissue cannot be explained by blood
contamination because in lysates of whole blood the BAFF
concentration was 
 
 
 
10-fold lower than in brain tissue lysates.
10 paired noninflammatory serum/CSF samples were
analyzed by ELISA. BAFF concentrations ranged from 153
to 845 pg/ml in CSF (mean 
 
 
 
 SD: 483 
 
 
 
 263 pg/ml) and
from 2,257 to 6,197 pg/ml in serum (4,268 
 
 
 
 1,295 pg/ml).
No significant correlation was found between BAFF values
in serum and CSF (R 
 
 
 
 0.35, P 
 
 
 
 0.31). The relatively high
level of BAFF in CSF (on average 10% of the serum concen-
tration) and the lack of correlation between serum and CSF
content suggest that the BAFF present in the CSF is at least
in part produced locally.
The functional relevance of the constitutive BAFF pro-
duction in the CNS is presently unknown. Although no
neurological deficits of BAFF-deficient mice have been de-
scribed yet, this does not exclude subtle functional changes
in the CNS.
 
BAFF production by cultured human astrocytes
 
Cultured human astrocytes constitutively contained a low
level of BAFF transcripts (Fig. 4 A), which was increased by
IFN-
 
 
 
, to a lesser extent by TNF-
 
 
 
 or IL-1
 
 
 
, but not by
IL-10 (Fig. 4 B), GM-CSF, or IL-4 (not depicted). The
strongest induction was seen with a combination of IFN-
 
 
 
and TNF-
 
 
 
 (Fig. 4 B). The amount of BAFF secreted by as-
trocytes paralleled the induction of transcription (Fig. 4 C).
An inhibitor of furin-like proteases, decanoyl-Arg-Val-Lys-
Arg-chloromethylketone, reduced the amount of secreted
BAFF by 96% (unpublished data), indicating that astrocytes
use furin-like proteases to release BAFF as do granulocytes
(3). The biological activity of the astrocyte-produced BAFF
was verified in a B cell proliferation assay (Fig. 4 E).
The level of BAFF released per cell after stimulation was
much greater in astrocyte cultures than by activated mono-
cytes (50 times) or macrophages (5 times; Fig. 4 D), which
released in our study similar BAFF levels as described previ-
ously (2). To exclude the possibility that the BAFF levels in
monocyte and macrophage cultures were artificially lowered
by paracrine BAFF consumption of B cells, PBMCs were
depleted of B cells before negatively selecting monocytes.
FACS analysis showed that, in the purified monocyte cul-
tures, essentially no BAFF binding cells could be detected.
 
BAFF and BAFF receptors in MS lesions
 
The transcript level of BAFF was 
 
 
 
10-fold higher in MS le-
sions as compared with normal CNS (P 
 
 
 
 0.01), reaching
approximately the same level as in lymphatic tissues (Fig. 2).
Immunostaining for BAFF was performed on 11 brain
specimens from four MS patients. In each specimen, BAFF
was immunolocalized on astrocytes (Fig. 3, E–N). In acute
MS lesions, BAFF localized to astrocytes outside of the in-
flammatory cuffs (Fig. 3 M). In chronic MS lesions, numer-
ous BAFF
 
 
 
 cells with the morphology of astrocytes were de-
tected in both the perivascular area and in the parenchyma
(Fig. 3, H–L and N). Double labeling for glial fibrillary
acidic protein (GFAP) and BAFF identified BAFF-express-
ing cells as astrocytes in both acute (Fig. 3, E–G) and chronic
MS lesions (Fig. 3, H–J). Confocal analysis revealed a dense
network of BAFF
 
 
 
 astrocytes in the perivascular area and in
the parenchyma of MS lesions (Fig. 3, H–J). Although the
most sensitive staining was observed with the BAFF-specific
mAb B1A3.2 (Fig. 3, A–C, E, G, H, J, K, M, and N), a sim-
ilar astrocytic staining was observed with the BAFF-specific
Figure 4. BAFF production by cultured astrocytes. (A) RT-PCR identi-
fied full-length BAFF and the splice variant  BAFF. To detect the constitu-
tive expression of both isoforms and the induction by cytokine stimulation 
(25 h), two different cycle numbers were used as indicated. (B and C) Regu-
lation by inflammatory cytokines. From the same stimulated astrocytes, 
RNA and cell culture supernatant were analyzed after 48 h by quantitative 
PCR (B) and ELISA (C). Error bars represent the SD. (D) Comparison of BAFF 
secretion by astrocytes, monocytes, and macrophages. After stimulation for 
48 h, cell culture supernatants were analyzed by ELISA. The means of two 
experiments with monocytes, three with macrophages, and two with astro-
cytes are shown. Error bars represent SEM. Astrocyte stimulation with LPS   
IFN-  was not determined (ND) because a series of experiments had 
shown that these cultures do not respond to LPS, in agreement with the 
absence of myeloid cells in these cultures. (E) Functional activity of astro-
cyte-derived BAFF in a B cell proliferation assay. The concentrated astrocyte 
supernatant was added at a final dilution of 1:10 to the B cell culture. 
Medium processed in the same way as the astrocyte supernatant served as 
negative control and recombinant BAFF served as positive control. BAFF-R:
Fc was used to block the BAFF effect. Error bars indicate the SD. 
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mAb A9C9.1 in normal brain (Fig. 3 D) and MS lesions
(Fig. 3 L). BAFF-R was detected on a subset of inflamma-
tory cells in the vicinity of BAFF-expressing astrocytes,
mainly in the perivascular area (Fig. 3 P).
Our histological observation of enhanced BAFF expres-
sion on astrocytes in MS lesions is in harmony with the in
vitro induction of BAFF on astrocytes by inflammatory cy-
tokines. However, it should be noted that the histological
detection of BAFF is presumably insensitive. For example, in
mice, BAFF staining was unsuccessful (13), and in tonsils
we detected BAFF only on a few scattered cells (Fig. 3 O)
despite its abundant transcription. This indicates that, by
immunohistochemical staining, the number and cell types
expressing BAFF might be underestimated. Because macro-
phages are abundant in MS lesions and produce BAFF in
vitro, the elevated BAFF expression in MS lesions might be
due to BAFF produced by both astrocytes and macrophages.
Our in vitro findings that appropriately stimulated astrocytes
produce five times more BAFF per cell than highly activated
macrophages might explain why in MS lesions BAFF is im-
munolocalized preferentially to astrocytes.
Our findings suggest the following scenario: BAFF pro-
duced by astrocytes promotes the survival of BAFF-R–express-
ing B cells in MS brains, allowing the persistence and clonal
expansion of B cells in the CNS (7–9, 11). The oligoclonal Ig
in the CSF are remarkably stable for many years (6), consistent
with the long-term survival of local plasma cells. Recently, it
has been shown that BCMA, a receptor for BAFF and APRIL,
is critical for the long-term survival of plasma cells (14). Locally
produced BAFF might contribute to plasma cell survival in the
CNS. Indeed, our quantitative PCR indicated that BCMA
was up-regulated in MS brain specimens (Fig. 5). Our conclu-
sions are consistent with two animal studies. First, the normal
brain microenvironment supports development of antigen-
directed humoral immunity in rodents (15). Second, increased
BAFF gene expression was detected in the CNS of animals
with experimental autoimmune encephalomyelitis, although in
this paper, neither BAFF-producing nor BAFF receptor–
expressing cells were described previously (16).
Local BAFF production within MS lesions might also
promote T cell activation because BAFF has also been rec-
ognized as a costimulator for T cells (17). The elevated ex-
pression of BAFF in MS lesions was not reflected by an in-
crease of BAFF in the CSF (reference 18 and unpublished
data). This resembles observations with CCL-2/MCP-1.
This chemokine is constitutively present in the CSF and it is
abundantly expressed in MS lesions, but its concentration in
the CSF is even reduced in MS (19). Presumably, the ratio
of production and consumption by inflammatory cells deter-
mines the CSF level.
 
BAFF and BAFF receptors in primary CNS lymphomas
 
Primary CNS lymphomas are extranodal lymphomas that are
confined to the CNS in the absence of systemic disease. Pri-
mary CNS lymphomas are typically of B cell origin for still
unknown reasons (5).
Although BAFF receptors had not been analyzed in pri-
mary CNS lymphomas before, we report that in these CNS
tumors, the transcript levels of all three BAFF receptors
greatly exceeded that in normal brain and reached the same
level as in lymphatic tissue (Fig. 5). Immunohistochemical
analysis detected BAFF-R in primary CNS lymphomas
rather homogeneously (Fig. 3 Q). A clear BAFF-R staining
was observed on tumor cells in six out of seven specimens of
the CNS lymphomas. Expression of the three BAFF recep-
tors in individual tumor samples was heterogeneous (Fig. 5).
The PCR data paralleled the histological data. The tumor
sample with the lowest BAFF-R transcript level was the
only one of the seven specimens without a clear BAFF-R
staining. This tumor showed the highest TACI expression
and the second highest BCMA level of the specimens ana-
lyzed (Fig. 5).
BAFF was transcribed in each of the five analyzed tumor
specimens, in three of them at a similar level as in normal
CNS, and in two of them at an elevated level (Fig. 2). The
CNS lymphoma tissue we investigated in this paper did not
contain parenchyma surrounding the tumors. However,
Figure 5. BAFF receptors in normal CNS, MS lesions, and primary 
CNS lymphomas. The expression level of BAFF-R, TACI, and BCMA was 
determined by quantitative PCR and is indicated as the percentage of the 
housekeeping gene PPIA. The mean values of 4 specimens from adenoids/
tonsils and of 12 specimens from normal CNS are shown. Individual ex-
pression levels are shown for the analyzed pathological tissue specimens 
from MS lesions or primary CNS lymphomas. Error bars indicate the SD. 
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based on our findings in normal brain and in inflammatory
MS lesions, it seems plausible to assume that BAFF released
by resident astrocytes supports the survival of BAFF-receptor–
expressing B cell lymphomas, which are otherwise found in
lymph nodes where BAFF is abundant. Primary CNS lym-
phomas reside at least partially behind an intact blood–brain
barrier (5), implicating the importance of the CNS-derived
BAFF as a survival factor. This local supply of BAFF to-
gether with the shielding of the brain microenvironment
from the immune system might provide a favorable basis
for tumor development. Recent animal studies are consistent
with this conclusion; in the absence of TNF-
 
 
 
, BAFF-over-
expressing mice develop lymphomas (20), showing that BAFF
in combination with a reduced tumor immunosurveillance
facilitates lymphoma development. Our findings have thera-
peutic implications by suggesting that it might be beneficial
to inhibit the local availability of BAFF in and around the
CNS lymphoma.
In conclusion, we have extended the spectrum of BAFF
sources to astrocytes and demonstrate that BAFF is constitu-
tively present in the CNS. In MS lesions, BAFF expression
was elevated to levels of lymphatic tissues. Local BAFF pro-
duction in the CNS might promote B cell survival in MS
and primary CNS lymphoma.
 
MATERIALS AND METHODS
 
Tissue specimens, CSF, and serum.
 
Control tissue specimens were
obtained from autopsy material of persons who had died of acute accidents:
normal brain including gray and white matter of the cerebrum and cerebel-
lum (17 tissue blocks from four adult persons), heart, skeletal muscle, lung,
liver, skin with adipose tissue, pancreas, and kidney. Tonsils and adenoids
were obtained after operations. Eight brain lesions of six MS patients were
examined by RT-PCR. One case was published (case 2 in reference 21),
the other specimens were obtained from the Institute of Neurology in Lon-
don (courtesy of L. Cuzner and J. Newcombe). They were classified as
acute based on the presence of oil red O positive macrophages and perivas-
cular infiltrates. Frozen brain specimens from 11 blocks of four MS patients
were examined immunohistologically: two blocks from an acute lesion (pa-
tient 1; case 2 in reference 21), six blocks containing chronic active and
chronic inactive lesions (patient 2), a chronic active plaque (patient 3), and
two blocks containing chronic active and chronic inactive lesions (patient 4;
MS 79 in reference 10). Seven surgical specimens from six primary CNS
lymphomas (diffuse large B cell lymphoma, tumor cell content 
 
 
 
80%) were
analyzed by immunohistochemistry, and five by RT-PCR. Some of these
tumors contained an extensive GFAP positive gliosis. Paired CSF and serum
samples from 10 patients without inflammatory neurological disease were
investigated. The study was approved by the ethics committee of the Uni-
versity of Munich.
 
Cell culture.
 
Human astrocytes of embryonic origin were devoid of mi-
croglial cells or macrophages (22). These cells were stimulated with 10 or 25
ng/ml TNF-
 
 
 
, 100 U/ml IFN-
 
 
 
 (Roche), 50 ng/ml IL-1
 
 
 
, and 100 ng/ml
IL-10 (R&D Systems).
For the analysis of the biological activity of secreted BAFF, astrocytes
were switched to serum-free medium (Pan-Biotech) and stimulated with
IFN-
 
 
 
 
 
 
 
 TNF-
 
 
 
 for 3 d. The supernatant was concentrated 
 
 
 
200-fold and
a B cell proliferation assay was done essentially as described previously (17).
Monocytes were isolated by negative selection from CD19-depleted
PBMCs (both obtained from Miltenyi Biotec), differentiated to macro-
phages with 20 ng/ml M-CSF for a period of 9–11 d (2), and stimulated in
new medium. BAFF-binding cells were identified by myc-BAFF, biotinyl-
ated anti-myc mAb, and streptavidin-PE. Cells were stimulated with 300
U/ml IFN-
 
 
 
 
 
 
 
 25 ng/ml TNF-
 
 
 
 or 300 ng/ml LPS for 48 h.
 
PCR.
 
Quantitative PCR and the identification of BAFF isoforms was per-
formed  as described in the supplemental material (available at http://
www.jem.org/cgi/content/full/jem.20041674/DC1).
 
BAFF ELISA.
 
The anti–human BAFF mAb clone B4H7.2 was used for
coating, the biotin-labeled anti–human BAFF clone A9C9.1 was used for
detection, and recombinant human BAFF was used as a standard (all ob-
tained from Biogen Idec Inc.). To determine whether this ELISA can be
used to detect BAFF content in tissue lysates, 400 pg/ml BAFF was spiked in
a 1:50 and 1:20 dilution of the RIPA lysis buffer; 
 
 
 
95% of the spiked BAFF
was detected. Protein lysates of brain specimens and whole blood were ob-
tained using RIPA buffer and measured in a dilution of at least 1:40.
 
Immunohistochemistry.
 
Mabs recognizing BAFF (B1A3.2 and A9C9.1),
BAFF-R (9–1; 5–10 
 
 
 
g/ml), and IgG1 control were used. The mAb
B1A3.2 revealed a good staining with 20 
 
 
 
g/ml, the strongest BAFF-
expressing cells could still be seen with 10 
 
 
 
g/ml. mAb A9C9.1 was used at
35 
 
 
 
g/ml. Stainings were made on PFA or formalin-fixed cryosections with
the peroxidase antiperoxidase method or the avidin–biotin complex system
(DakoCytomation). The autoptic specimens of patient 4, which had been
fixed in PFA before freezing, were processed as described previously (10).
For double immunofluorescence staining, mouse anti-BAFF mAb B1A3.2
and rabbit anti-GFAP were applied simultaneously, followed by donkey
anti–mouse Alexa Fluor 488 or donkey anti–mouse biotin plus Cy2-conju-
gated streptavidin, and donkey anti–rabbit Alexa Fluor 594. Confocal im-
ages were taken on a TCS NT laser scanning microscope (Leica).
 
Online supplemental material.
 
Materials and methods for the quanti-
tative PCR and the identification of BAFF isoforms. Online supplemen-
tal  material is available at http://www.jem.org/cgi/content/full/jem.
20041674/DC1.
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